bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Bloo
Go back to bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Bloo| BLUEBIRD BIO (NASDAQ: BLUE) | Delayed: 4.97 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.97 | 52 Week High | $95.28 | |||
| Open | $4.97 | 52 Week Low | $35.37 | |||
| Day High | $4.97 | P/E | N/A | |||
| Day Low | $4.97 | EPS | $-1.81 | |||
| Volume | 5 | |||||
